A Systematic Review and Network Meta-Analysis to Assess the Relative Efficacy of Antipsychotics for the Treatment of Positive and Negative Symptoms in Early-Onset Schizophrenia

  title={A Systematic Review and Network Meta-Analysis to Assess the Relative Efficacy of Antipsychotics for the Treatment of Positive and Negative Symptoms in Early-Onset Schizophrenia},
  author={Rebecca C. Harvey and Anthony James and Gemma Elizabeth Shields},
  journal={CNS Drugs},
IntroductionEarly-onset schizophrenia (EOS) is a serious debilitating disorder with considerable morbidity and a reduced life expectancy; therefore, early diagnosis and effective treatments are particularly important. Negative symptoms are more prominent in adolescents and children (compared with adults), and are key predictors of worse functional and clinical outcomes in EOS. Therefore, this study aimed to explore the relative efficacy of antipsychotics used in the treatment of EOS, with a… 

Comparative efficacy and safety of antipsychotics in the treatment of schizophrenia: a network meta-analysis in a Japanese population

Diverse hierarchies in safety outcomes also support the implication that individual risk expectations for adverse events can guide clinical decisions, and additional efficacy and safety data are required to fully obtain a conclusive understanding.

Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: a systematic literature review and network meta-analysis

Lurasidone was associated with similar efficacy, less weight gain, and lower risk of all-cause discontinuation compared to other oral atypical antipsychotic monotherapies in adolescent schizophrenia.

Comparative Efficacy and Tolerability of Antipsychotics for Juvenile Psychotic Disorders

Some antipsychotics were effective and tolerated short term, but longer-term evidence was very limited and the overall paucity of trials and of adequate controls indicates that more well-designed randomized controlled trials are required for adequate assessment of antipsychotic drug treatment for juveniles.

What Role for Long-Acting Injectable Antipsychotics in Managing Schizophrenia Spectrum Disorders in Children and Adolescents? A Systematic Review.

Overall, these treatments have suggested good effectiveness and acceptable safety and tolerability, however, the problems and benefits linked to this type of antipsychotic formulation in the child and adolescent population require further study.

Treating Negative Symptoms in Schizophrenia: an Update

From this perspective, identification of biomarkers and/or endophenotypes permitting earlier diagnosis and intervention may serve to improve treatment efficacy as well as outcomes.

Gender differences in the use of atypical antipsychotics in early-onset schizophrenia: a nationwide population-based study in Brazil

Investigating gender differences in the use of atypical antipsychotics in patients with early-onset schizophrenia (EOS) assisted by the public health system in Brazil found gender differences, especially in the 13–17 year age group, which were slightly higher for males than for females.

Meta-Review: Network Meta-Analyses in Child and Adolescent Psychiatry.

Critical appraisal and comparison of recommendations of clinical practice guidelines for treatment of schizophrenia in children and adolescents: a methodological survey protocol

The quality of the development of CPGs for the treatment and management of schizophrenia in children and adolescents over time is assessed using the Appraisal of Guidelines for Research and Evaluation II (AGREE II) tool and to compare the recommendations and interventions described in these documents are compared.



Predictors of outcome in early-onset psychosis: a systematic review

EOP patients with poorer premorbid adjustment and prominent negative symptoms at initial presentation are at risk of poor outcome and should be the target of careful monitoring and more intensive interventions to address whether the disease course can be modified in this especially severely affected group.

Treatment of early-onset schizophrenia

Careful monitoring of metabolic side effects and age-appropriate intervention is particularly important, as children and adolescents appear to be more likely to develop metabolic abnormalities such as pronounced weight gain, which may significantly impact adherence as well as lead to other health issues.

Atypical antipsychotics for psychosis in adolescents.

This systematic review collates and critiques evidence obtained on the use of various atypical antipsychotic medications for adolescents with psychosis, finding no data on service utilisation, economic outcomes, behaviour or cognitive response.

A trial of quetiapine compared with risperidone in the treatment of first onset psychosis among 15- to 18-year-old adolescents

The results in this small trial show that adolescent patients may benefit more from treatment with risperidone than quetiapine, however, those susceptible to side effects, particularly hyperprolactinaemia, may be more suitable for treatment with quetuapine.

Practice parameter for the assessment and treatment of children and adolescents with schizophrenia.

  • J. McClellanS. Stock
  • Psychology, Medicine
    Journal of the American Academy of Child and Adolescent Psychiatry
  • 2013

A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia.

Both 10- and 30-mg/day doses of aripiprazole were superior to placebo in the acute treatment of adolescents with schizophrenia and was generally well tolerated.

A systematic review of the long-term outcome of early onset schizophrenia

The early manifestation of schizophrenia in childhood and adolescence still carries a particularly poor prognosis, and longer follow-up periods, male sex, and patients having been diagnosed before 1970 contribute predominantly to the rather poor course of EOS.